Clinical application of all‐<i>trans</i> retinoic acid (tretinoin) for adult t‐cell leukaemia

Maeda, Yasuhiro; Naiki, Yoshito; Sono, Hiroshi; Miyatake, Jun-ichi; Sumimoto, Yoshiyasu; Sakaguchi, Mika; Matsuda, Mitsuhiro; Kanamaru, Akihisa

doi:10.1046/j.1365-2141.2000.02033.x

Cited by 10 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Natural retinoids, such as all-trans retinoic acid (ATRA), are currently used as chemopreventive and therapeutic agents in human cancers, particularly acute promyelocytic leukemia (23 -25). The clinical usefulness of ATRA in indolent ATL was also reported (26). Unfortunately, the use of natural retinoids is limited due to their side effects and acquired in vitro and in vivo resistance after prolonged exposure (27).…”

Section: Introductionmentioning

confidence: 97%

NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-κB signal pathway

Okudaira¹,

Tomita²,

Uchihara³

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Adult T-cell leukemia (ATL) is caused by human T-cell leukemia virus type I (HTLV-I) and remains incurable. NIK-333, a novel synthetic retinoid, prevents the recurrence of human hepatoma after surgical resection of primary tumors. We explored the effects of NIK-333 on HTLV-I-infected T-cell lines and ATL cells. NIK-333 inhibited cell proliferation, induced G 1 arrest, and resulted in massive apoptosis in all tested HTLV-I-infected T-cell lines and ATL cells, whereas little effect was observed on normal peripheral blood mononuclear cells. NIK-333 treatment decreases the levels of cyclin D1, cyclin D2, cIAP2, and XIAP proteins. Further analysis showed that NIK-333 inactivated nuclear factor-KB in HTLV-I-infected T-cell lines. In animal studies, treatment with NIK-333 (100 mg/kg given orally every other day) produced partial inhibition of growth of tumors of a HTLV-I-infected T-cell line transplanted s.c. in severe combined immunodeficient mice. Our results indicate that NIK-333 is a potentially useful therapeutic agent for patients with ATL. [Mol Cancer Ther 2006;5(3):704 -12]

show abstract

Section: Introductionmentioning

confidence: 97%

NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-κB signal pathway

Okudaira¹,

Tomita²,

Uchihara³

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…We previously reported that all-trans retinoic acid (ATRA) inhibited cell growth and induced apoptosis in HTLV-I ( þ ) T-cell lines as well as fresh ATL cells obtained from ATL patients. [1][2][3][4] Tsukasaki et al 5 reported an interesting case in which ATRA induced complete remission for a patient with double hematological malignancies, acute promyelocytic leukemia and ATL. ATL is characterized by infiltration of various tissues by circulating ATL cells.…”

mentioning

confidence: 99%

All-trans retinoic acid reduced skin involvement of adult T-cell leukemia

et al. 2004

View full text Add to dashboard Cite

“…Novel strategies such as the use of unlabelled or radiolabelled anti‐CD25 monoclonal antibody (mAb), deoxycoformycin and interferons (IFN) alpha, beta and gamma have also been used, but only occasional patients have achieved a durable response (Tamura et al , 1987; Ichimaru et al , 1988; Waldmann et al , 1988; Mercieca et al , 1994; Waldmann, 1994). Isolated case reports of a response to etoposide monotherapy (Kojima et al , 1993), allogeneic bone marrow transplantation (Ljungman et al , 1994) and, more recently, a case responding to all‐ trans retinoic acid have been documented (Maeda et al , 2000). Extremely rare spontaneous remissions have been reported (Schnitzer et al , 1983; Mattock et al , 1986).…”

mentioning

confidence: 99%

Interferon α and zidovudine therapy in adult T‐cell leukaemia lymphoma: response and outcome in 15 patients

Matutes

Taylor²,

Cavenagh

et al. 2001

Br J Haematol

View full text Add to dashboard Cite

Adult T‐cell leukaemia lymphoma (ATLL) is an aggressive disease caused by the human T‐lymphotropic virus 1 (HTLV‐I) with a short survival. Responses to interferon alpha (IFN‐α) and zidovudine (AZT) have been documented but not with long‐term follow‐up. We treated 15 ATLL patients with IFN and AZT. Eleven patients had acute ATLL, two had lymphoma and two smouldering ATLL, with progression. The main features were: organomegaly (14), skin lesions (10), high white blood cell (WBC) count (11) and hypercalcaemia (9). Eleven patients had previously received chemotherapy and one had received an autograft. At the time of the study, seven patients had progressive disease and eight were in partial or complete clinical remission. Responses (PR) lasting 2+ to 44+ months were seen in 67%; 26% did not respond (NR) and one patient was not evaluable. Hypercalcaemia predicted a poor outcome but differences were not significant. Eight of the 15 patients have died 3–41 months from diagnosis. Median survival for the 15 patients was 18 months. Survival of the NR ranged from 4 to 20 months; six PR patients are alive 8–82 months from diagnosis. The differences in survival between NR (median: 6 months) and PR (55% of patients alive at 4 years) were statistically significant (P = 0·002). In conclusion, IFN and AZT improves the outcome of ATLL patients and helps maintain responses.

show abstract

Clinical application of all‐trans retinoic acid (tretinoin) for adult t‐cell leukaemia

Cited by 10 publications

References 4 publications

NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-κB signal pathway

NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-κB signal pathway

All-trans retinoic acid reduced skin involvement of adult T-cell leukemia

Interferon α and zidovudine therapy in adult T‐cell leukaemia lymphoma: response and outcome in 15 patients

Contact Info

Product

Resources

About